Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057 · View on ClinicalTrials.gov ↗

Study Summary

This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Interventions

  • DRUG Hydroxychloroquine Sulfate
  • DRUG LY3214996

Study Locations (4)

Massachusetts

  • Massachusetts General Hospital Cancer Center — Boston
  • Dana-Farber Cancer Institute — Boston
  • Beth Israel Deaconess Medical Center — Boston

North Carolina

  • The University of North Carolina at Chapel Hill — Chapel Hill

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2020-05-27
Est. Completion 2024-02-05
Phase Phase 2

Sponsor

Kimberly Perez, MD

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04386057

The ClinicalTrials.gov registry entry for NCT04386057 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kimberly Perez, MD, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions — of which Hydroxychloroquine Sulfate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04386057 reports 4 study locations spanning 2 distinct geographic areas — top geographies include Massachusetts, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04386057 about?

NCT04386057 is a clinical study titled "LY3214996 +/- HCQ in Pancreatic Cancer". This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

What is the current status of trial NCT04386057?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-05-27. Estimated completion is 2024-02-05.

What conditions does trial NCT04386057 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04386057?

The interventions under investigation include: Hydroxychloroquine Sulfate (DRUG), LY3214996 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04386057?

This trial is sponsored by Kimberly Perez, MD, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04386057 being conducted?

This trial has 4 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial